WeTrials
Recruiting

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

What is this study?

This study is testing a new experimental medicine called MOMA-313, both by itself and combined with an existing cancer drug called Olaparib. Researchers want to see if these treatments are safe and helpful for people with advanced solid tumors that have specific DNA repair issues.

Who can participate?

You may be able to join if you are 18 or older and have an advanced solid tumor—such as breast, prostate, pancreatic, or ovarian cancer—that has not responded to standard treatments and has certain gene changes.

What will happen?

Participants will receive the study medication orally, either alone or with the PARP inhibitor, while doctors closely monitor your health, side effects, and how well the treatment works.

Where and when?

This study is currently recruiting patients and is taking place at multiple medical centers, including locations in Goodyear, Arizona, and La Jolla and San Francisco, California.

Key Points
  • 1Testing a new experimental drug called MOMA-313 for advanced solid tumors
  • 2May involve taking the new drug alone or combined with a standard targeted cancer medicine
  • 3Currently recruiting participants at select locations in Arizona and California

Related video

Dana-Farber: polymerase theta biology in BRCA cancers (research background)

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Advanced Solid TumorMetastatic Solid TumorProstate CancerPancreas CancerBreast CancerOvarian CancerHomologous Recombination Deficiency

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.